Case Report
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Nov 26, 2021; 9(33): 10345-10354
Published online Nov 26, 2021. doi: 10.12998/wjcc.v9.i33.10345
Individualized treatment of breast cancer with chronic renal failure: A case report and review of literature
Jie-Hui Cai, Jie-Hua Zheng, Xiao-Qi Lin, Wei-Xun Lin, Juan Zou, Yao-Kun Chen, Zhi-Yang Li, Ye-Xi Chen
Jie-Hui Cai, Jie-Hua Zheng, Xiao-Qi Lin, Wei-Xun Lin, Juan Zou, Yao-Kun Chen, Zhi-Yang Li, Ye-Xi Chen, Department of General Surgery, The Second Affiliated Hospital of Shantou University Medical College, Shantou 515041, Guangdong Province, China
Xiao-Qi Lin, Wei-Xun Lin, Juan Zou, Yao-Kun Chen, Breast Disease Research Center, The Medical Research Institute of Shantou Doctoral Association, Shantou 515041, Guangdong Province, China
Author contributions: Cai JH and Zheng JH are the patient’s doctors, and they reviewed the literature and contributed to manuscript drafting; Lin WX, Zou J, and Li ZY reviewed the literature, analyzed and explained the results of laboratory examinations, imaging examinations and pathological examinations; Lin XQ and Chen YK collected patient information and examination data, designed and produced the figures and tables; Chen YX reviewed the literature, contributed to manuscript drafting and revised the manuscript; all authors participated in the discussion and formulation of patient chemotherapy regimens and drug dosage adjustments, and issued final approval for the version to be submitted.
Informed consent statement: Written informed consent was obtained from the patient for publication of this case report. A copy of the written consent is available for review by the editor of this journal.
Conflict-of-interest statement: The authors report no conflicts of interest in this work.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ye-Xi Chen, MD, Chief Doctor, Professor, Department of General Surgery, The Second Affiliated Hospital of Shantou University Medical College, No. 69 North Dongxia Road, Shantou 515041, Guangdong Province, China. yxchen3@stu.edu.cn
Received: July 8, 2021
Peer-review started: July 8, 2021
First decision: August 18, 2021
Revised: September 5, 2021
Accepted: September 22, 2021
Article in press: September 22, 2021
Published online: November 26, 2021
Processing time: 136 Days and 22.2 Hours
Core Tip

Core Tip: Renal failure is an important factor limiting the treatment of breast cancer because of the nephrotoxicity of anticancer drugs. There are few successful case reports of the combination of docetaxel, trastuzumab and pertuzumab (THP), especially pertuzumab, as a preoperative neoadjuvant treatment regimen for breast cancer patients with chronic renal failure (CRF) and few pharmacokinetic studies are available on renal failure in these patients. This report describes a breast cancer patient with CRF, which shows the safety of pertuzumab and effectiveness of the THP preoperative neoadjuvant treatment regimen.